United States - English - NLM (National Library of Medicine)

remedyrepack inc. - mometasone (unii: 8hr4qj6dw8) (mometasone - unii:8hr4qj6dw8) - mometasone 50 ug - mometasone furoate nasal spray 50 mcg is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older. mometasone furoate nasal spray 50 mcg is indicated for the relief of nasal congestion associated with seasonal allergic rhinitis, in adults and pediatric patients 2 years of age and older. mometasone furoate nasal spray 50 mcg is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older. mometasone furoate nasal spray 50 mcg is indicated for the treatment of nasal polyps in patients 18 years of age and older. mometasone furoate nasal spray is contraindicated in patients with known hypersensitivity to mometasone furoate or any of its ingredients. teratogenic effects: pregnancy category c: there are no adequate and well-controlled studies in pregnant women. mometasone furoate nasal spray 50 mcg, like other corticosteroids, should be

Ireland - English - HPRA (Health Products Regulatory Authority)

auden mckenzie (pharma division) ltd - mometasone furoate - cream - 0.1 percent weight/weight - corticosteroids, potent (group iii); mometasone

Ireland - English - HPRA (Health Products Regulatory Authority)

auden mckenzie (pharma division) ltd - mometasone furoate - ointment - 0.1 percent weight/weight - corticosteroids, potent (group iii); mometasone

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 50 ug - nasonex® nasal spray 50 mcg is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older. nasonex nasal spray 50 mcg is indicated for the relief of nasal congestion associated with seasonal allergic rhinitis, in adults and pediatric patients 2 years of age and older. nasonex nasal spray 50 mcg is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older. nasonex nasal spray 50 mcg is indicated for the treatment of nasal polyps in patients 18 years of age and older. nasonex nasal spray is contraindicated in patients with known hypersensitivity to mometasone furoate or any of its ingredients. teratogenic effects: pregnancy category c: there are no adequate and well-controlled studies in pregnant women. nasonex nasal spray 50 mcg, like other corticosteroids, should be used during pregnancy only if the potential benefits justify the p

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 220 ug - asmanex® twisthaler® is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 4 years of age and older. limitations of use asmanex twisthaler is not indicated for the relief of acute bronchospasm. asmanex twisthaler is not indicated in children less than 4 years of age. asmanex twisthaler is contraindicated: - status asthmaticus: in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. - hypersensitivity: in patients with known hypersensitivity to milk proteins or any ingredients of asmanex twisthaler [see warnings and precautions (5.3) and description (11)]. risk summary there are no adequate and well-controlled studies of asmanex twisthaler in pregnant women. there are clinical considerations with the use of asmanex twisthaler in pregnant women [see clinical considerations] . in animal reproduction studies with pregnant mice, rats, or rabbits, mometasone furoate caused increased fetal malfo

United States - English - NLM (National Library of Medicine)

stat rx usa llc - mometasone furoate (unii: 04201gdn4r) (mometasone furoate - unii:04201gdn4r) - mometasone furoate cream 0.1% is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. mometasone furoate cream 0.1% may be used in pediatric patients 2 years of age or older, although the safety and efficacy of drug use for longer than 3 weeks have not been established (see precautions – pediatric use  section). since safety and efficacy of mometasone furoate cream 0.1% have not been established in pediatric patients below 2 years of age, its use in this age group is not recommended. mometasone furoate cream 0.1% is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate ointment usp, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or older. there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate ointment 0.1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/or delayed ossification. mometasone furoate also caused dystocia and related complications when administered to rats during the end of pregnancy. in

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate, usp ointment 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or older. none. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate, usp ointment 0.1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/or delayed ossification. mometasone furoate also caused dystocia and related co

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate cream usp, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or older. none. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/or delayed ossification. mometasone furoate also caused dystocia and related complications when administered to

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate cream usp, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or older. none. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/or delayed ossification. mometasone furoate also caused dystocia and related complications when administered to